Echosens

10/09/2026

👋 We are pleased to be at the Paris MASH Meeting today, connecting with healthcare professionals and contributing to the conversation around diagnosis and management.

®

09/09/2026

👩‍⚕️Dr. Alisha Mavis’ commitment to pediatric MASLD is just as personal as it is clinical.

Her experience is grounded in pediatric hepatology, but she brings to her work a long-standing passion for helping children build healthier futures.

That perspective matters in pediatric MASLD, where progress rarely comes from one-size-fits-all treatment. Instead, improvement happens when clinicians take the disease seriously, understand the child in front of them, and personalize care in a way families can carry forward.

🗒️Read Dr. Mavis’ new white paper for more on early recognition, pediatric-specific risk, and thoughtful long-term management of pediatric MASLD. https://www.echosens.com/en-us/wp-mavis/

07/09/2026

Join Echosens at IAT MUC 2026 in Munich!

Our team will be attending the Interdisciplinary Obesity Days (IAT MUC), bringing together healthcare experts committed to advancing obesity care through innovation and patient-centered approaches.

Stop by to meet us and learn how FibroScan® supports non-invasive liver health assessment in patients living with obesity and metabolic diseases.
📅 September 11–12, 2026
🕐 From 8:45 AM
📍 The Rilano Hotel München, Munich

We look forward to connecting with you

01/09/2026

We're excited to be at the 2026 edition of Congress in Mexico City until tomorrow!

📍 Stop by booth #3 and meet our team to explore our latest product innovations.
Discover the next generation of ® featuring Guided VCTE™ technology and see it in action through our live scanning demonstrations.

We look forward to connecting with you!

31/08/2026

Time with patients is limited so every minute needs to count.

When assessments can happen in-office, with immediate results and something tangible to discuss, conversations become more focused, meaningful, and actionable.

🎥 Hear from primary care physician Dr. Radhika Vayani as she explains how FibroScan ® makes patient visits more efficient and impactful, delivering fast, point-of-care liver assessment that fits seamlessly into primary care workflows and helps clinicians make the most of the time they have with patients.

➡️ Get a closer look at the impact of point-of-care liver assessments in her white paper:
https://www.echosens.com/wp-vayani/

25/08/2026

One of the most concerning aspects of pediatric MASLD is the long disease runway.
When steatosis and insulin resistance begin in childhood, they don’t remain static, they interact with every developmental stage that follows, including the major hormonal and metabolic shifts of puberty and early adulthood.

As Dr. Alisha Mavis explains, pediatric MASLD can accelerate a lifetime of metabolic disease risk much earlier than many people realize, increasing concern not only for liver disease progression, but also for cardiovascular disease, type 2 diabetes, and premature mortality. That’s why early recognition is imperative.

Read Dr. Mavis’ new white paper for guidance on earlier identification, pediatric-specific risk assessment, and more thoughtful longitudinal management of pediatric MASLD. https://www.echosens.com/en-us/wp-mavis/

21/08/2026

Positive reinforcement isn’t just encouraging, it’s clinically powerful.

Celebrating small wins and showing patients that their efforts are making a measurable difference
builds confidence and encourages continued progress.

In her white paper titled, “Putting Patients First: Rethinking Metabolic Health in Everyday Primary Care,” Dr. Radhika Vayani highlights how repeat FibroScan ® assessments provide tangible, motivating feedback. Patients see the results of their lifestyle changes, stay engaged, and look forward to the next milestone, turning care into a collaborative, hopeful journey.

➡️ Read the full paper: https://www.echosens.com/wp-vayani/

18/08/2026

For more than a decade, Dr. Alisha Mavis cared for children with MASLD as a pediatric hepatologist. And often, at first glance, these kids looked completely fine.

➡️ That’s part of what makes pediatric MASLD so misunderstood. It’s also too often viewed as simply a “lifestyle disease”, when in reality, pediatric MASLD is a complex, often silent metabolic condition influenced by genetics, early-life exposures, maternal health, and more.

📄 In this new white paper, Dr. Mavis explores why pediatric MASLD can be difficult to recognize early, how pediatric disease differs from adult disease, and why passive “wait and see” approaches do not work: https://www.echosens.com/en-us/wp-mavis/

13/08/2026

Motivation grows when patients can connect small changes to real results.

When progress is measurable, even small measurable changes, it reinforces that everyday choices matter and builds momentum toward bigger, sustained improvements.

➡️ In her white paper, Dr. Radhika Vayani explains how FibroScan ® supports more effectivepatient conversations, turning incremental improvements into positive feedback that inspires confidence, motivation, and hope: https://www.echosens.com/wp-vayani/

10/08/2026

For decades, healthcare has screened for chronic disease one organ at a time.

Cardiology looks at the heart. Nephrology looks at the kidneys. Hepatology looks at the liver.

But metabolic disease doesn’t follow the boundaries of medical specialties.

The same underlying dysfunction can contribute to obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, and liver disease—often years before symptoms appear.

The challenge isn’t identifying disease after it develops. It’s recognizing interconnected risk earlier and understanding what is happening across the body before disease compounds.

Jon Gingrich, CEO of Echosens North America, believes that new cardiovascular-kidney-metabolic (CKM) guidance from the American Heart Association reflects a growing shift toward a more integrated view of chronic disease—one that focuses on identifying risk earlier, understanding how conditions interact, and intervening before irreversible damage occurs.

Read Jon’s POV: https://kevinmd.com/2026/06/stop-screening-for-chronic-disease-one-organ-at-a-time.html

Cardiovascular-kidney-metabolic syndrome reframes chronic disease as connected. See why metabolic health screening still misses the liver's silent warning.